Meiwuhua (1731-TW) Group’s White (4108-TW) Today (19) held the Fa said, general manager Li Yiling said that due to the impact of the epidemic, the new drug White Blood for the treatment of cancer-related fatigue, and the new drug for the treatment of moderate and severe pain, White Pain, the growth rate has slowed down. It is expected that with the domestic epidemic situation. Slowing down and international clinical trials continue, the annual revenue is still expected to increase by double digits.
White blood treasure has been adopted by more than 70 medical institutions, including 18 large medical centers such as Chang Gung, Sanzong and Beirong, and nearly 400 oncologists have prescribed prescriptions. In addition, it has been approved for health insurance benefits since March last year, providing for breast cancer patients.
In addition to being used in cancer-related fatigue cancer and breast cancer, White Blood Treasure has also been extended to other indications. Li Yiling pointed out that the immunosuppressant market is expected to reach US$56 billion in 2025. White Blood Treasure is an immune preparation. The new drug can be combined with anticancer drugs, which is expected to enhance the benefits of combined therapy. At present, clinical trials of combined chemoradiotherapy for breast cancer and esophageal cancer patients have been conducted in 5 medical centers in China, and the case is expected to be completed by the end of the year.
In addition, the refined Astragalus polysaccharide extract in White Blood Treasure can induce the human body to have both RNA to fight the virus for mild or asymptomatic infection of the new coronary pneumonia, and can also help moderate and severe patients to inhibit virus replication and avoid excessive inflammation caused by of cytokine storm, reducing the production of pulmonary fibrosis.
Li Yiling said that at present, the clinical trial of White Blood Treasure in the new coronary pneumonia has been used in several cases, and the data has been collated and analyzed, and the data results will be published in international medical journals in the future.
